Cogentix Medical Postpones May 20, 2016 Annual Meeting in Response to Court Ruling; New Meeting Date Set for May 24, 2016 at 12:00 P.M. Central Daylight Time

USA Profile Username: jon@newsinnovations.com / edit profile Cogentix Medical Postpones May 20, 2016 Annual Meeting in Response to Court Ruling; New Meeting Date Set for May 24, 2016 at 12:00 P.M. Central Daylight Time PR Newswire MINNEAPOLIS, May 20, 2016 MINNEAPOLIS, May 20, 2016 /PRNewswire/ -- Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical device company with innovative and proprietary products serving urology and airway management markets, announced today that its board of directors has postponed the 2016 Annual Meeting of Stockholders previously scheduled for May 20, 2016 in light of the Chancery Court in the State of Delaware granting a Preliminary Injunction Motion brought by a director on the Board of Cogentix Medical. The Court ruled that the Cogentix Board of Directors may not take steps to implement the previously disclosed Board Reduction Plan to the extent it would reduce the number of Board seats to five or the number of Class I seats to one. The new Annual Meeting date will be Tuesday, May 24, 2016 at 12:00 P.M. Central Daylight Time. The meeting location will be announced on Monday, May 23, 2016. About Cogentix Medical Cogentix Medical, Inc., headquartered in Minnetonka, Minnesota, with additional operations in New York, Massachusetts, The Netherlands and the United Kingdom, is a global medical device company.  We design, develop, manufacture and market products for flexible endoscopy with our unique product lines featuring a streamlined visualization system and proprietary sterile disposable microbial barrier, known as EndoSheath technology, providing users with efficient and cost effective endoscope turnover while enhancing patient safety. We also commercialize the Urgent® PC Neuromodulation System, an FDA-cleared device that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). OAB is a chronic condition that affects approximately 42 million U.S. adults. The symptoms include urinary urgency, frequency and urge incontinence.  We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on Cogentix Medical and our products, please visit us at www.cogentixmedical.com. 'CGNT-G' For Further Information: EVC Group Doug Sherk/Brian Moore (Investors) 415-652-9100/310-579-6199     SOURCE Cogentix Medical, Inc. Web Site: http://www.cogentixmedical.com Follow Us To change the settings for your profile(s) or email delivery, go to https://prnmedia.prnewswire.com/profile/?action=editProfile and select the profile you would like to edit. You can select the industries, subjects, languages, geographical areas, companies, delivery options and delivery frequencies of your choice. In addition to current press releases, you can also find archived news, corporate information, photos, tradeshow news and much more on the PR Newswire for Journalists website: https://prnmedia.prnewswire.com To contact us, email: mediasite@prnewswire.com Please do not reply to this email; this is an automatically generated message. Copyright © PR Newswire Association LLC. All Rights Reserved. A UBM plc company. Our mailing address is: 350 Hudson Street, Suite 300 New York, NY 10014-4504